TABLE 1.
Clinico-pathologic characterization of CIC fusions.
| Clinico-pathologic Characteristics a | CIC::DUX4 | Antonescu et al. (2017) CIC::DUX4 data | Murphy et al. (2024) CIC::DUX4 data | CIC::NUTM1 | CIC::FOXO4 | CIC::LEUTX |
|---|---|---|---|---|---|---|
| Age (years) | ||||||
| Median | 29.5 | 31 | 28 | 15.5 | 36.5 | 7 |
| Range | 11–82 | 10–81 | 15–67 | 2–61 | 13–63 | 2–19 |
| Gender (n) | ||||||
| Male | 14 | 33 | 2 | 8 | 3 | 3 |
| Female | 18 | 24 | 3 | 6 | 1 | 6 |
| Metastatic rate | 22/29 (76%) | 30/57 (53%) | 2/5 (20%) | 3/12 (25%) | 3/4 (75%) | Not available |
| Died of disease | 15/24 (63%) | 23/57 (40%) | 2/5 (20%) | 8/11 (73%) | 2/4 (50%) | Not available |
a
Based on available clinical data. Clinico-pathologic data for CIC fusions with a defined binding partner were identified through PubMed, utilizing keywords of: (“CIC-DUX4, case report”), (“CIC-NUTM1, case report”), (“CIC-FOXO4, case report”), and (“CIC-LEUTX, case report”). In addition to the individual case reports, two published studies that specifically identified CIC::DUX4 fusions in patients and provided clinical data were included.